Complete financial analysis of Marker Therapeutics, Inc. (MRKR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Marker Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Mediwelcome Healthcare Management & Technology Inc. (2159.HK) Income Statement Analysis – Financial Results
- Pacific Image Electronics Co., Ltd. (6228.TWO) Income Statement Analysis – Financial Results
- Zenrin Co., Ltd. (9474.T) Income Statement Analysis – Financial Results
- Evil Empire Designs, Inc. (EVVL) Income Statement Analysis – Financial Results
- RCL Foods Limited (RCLFF) Income Statement Analysis – Financial Results
Marker Therapeutics, Inc. (MRKR)
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.31M | 9.00M | 1.24M | 466.79K | 213.19K | 205.99K | 183.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.05K | 120.72K |
| Cost of Revenue | 10.42M | 3.68M | 3.16M | 18.88M | 12.76M | 124.00M | 5.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.63K | 38.60K |
| Gross Profit | -7.11M | 5.32M | -1.92M | -18.41M | -12.55M | -123.79M | -5.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 22.42K | 82.12K |
| Gross Profit Ratio | -214.60% | 59.13% | -154.70% | -3,944.85% | -5,887.41% | -60,094.84% | -2,768.39% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 89.50% | 68.03% |
| Research & Development | 10.42M | 26.14M | 27.79M | 18.88M | 12.76M | 124.00M | 5.25M | 3.80M | 1.71M | 189.00K | 661.63K | 1.06M | 203.73K | 290.05K | 93.04K | 182.34K | 425.57K | 173.17K | 248.36K | 1.04M | 1.73M | 833.59K | 0.00 | 341.19K | 294.92K |
| General & Administrative | 7.48M | 12.82M | 12.92M | 10.47M | 9.98M | 24.38M | 6.41M | 4.69M | 4.45M | 3.18M | 2.00M | 4.42M | 2.43M | 3.65M | 4.10M | 1.31M | 2.08M | 708.71K | 593.67K | 1.61M | 4.01M | 1.41M | 379.86K | 1.13M | 834.02K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.48M | 12.82M | 12.92M | 10.47M | 9.98M | 24.38M | 6.41M | 4.69M | 4.45M | 3.18M | 2.00M | 4.42M | 2.43M | 3.65M | 4.10M | 1.31M | 2.08M | 708.71K | 593.67K | 1.61M | 4.01M | 1.41M | 379.86K | 1.13M | 834.02K |
| Other Expenses | 0.00 | -232.97K | -2.41M | 0.00 | 0.00 | 116.05M | -183.06K | 1.83K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.74K | 7.48K | 5.97K | 6.37K | 147.53K | 37.45K | 42.37K | 40.77K | 0.00 | 20.64K | 17.71K |
| Operating Expenses | 17.89M | 38.96M | 40.72M | 29.35M | 22.74M | 148.38M | 11.48M | 8.26M | 6.16M | 3.37M | 2.66M | 5.48M | 2.64M | 3.94M | 4.19M | 1.50M | 2.51M | 888.25K | 989.56K | 2.68M | 5.78M | 2.28M | 379.86K | 1.49M | 1.15M |
| Cost & Expenses | 17.89M | 38.96M | 40.72M | 29.35M | 22.74M | 148.38M | 11.48M | 8.26M | 6.16M | 3.37M | 2.66M | 5.48M | 2.64M | 3.94M | 4.19M | 1.50M | 2.51M | 888.25K | 989.56K | 2.68M | 5.78M | 2.28M | 379.86K | 1.49M | 1.19M |
| Interest Income | 539.16K | 248.06K | 5.70K | 148.74K | 1.08M | 253.72K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.81K | 0.00 | 0.00 | 0.00 | 3.96K | 0.00 | 0.00 | 125.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.93K | 575.54K | 1.76M | 745.07K | 679.33K | 1.24M | 1.19M | 778.18K | 1.38M | 446.60K | 116.82K | 0.00 | -5.78M | -2.28M | -379.86K | 0.00 | 0.00 |
| Depreciation & Amortization | 2.79M | 3.68M | 3.16M | 1.08M | 286.58K | 148.17M | 11.48M | 8.49M | -27.90M | -26.94M | -466.28K | 1.11M | 1.29M | 93.84K | 3.74K | 7.48K | 5.97K | 6.37K | 71.51K | 37.45K | 42.37K | 40.89K | -4.68K | 20.64K | 17.71K |
| EBITDA | -11.79M | -19.79M | -36.32M | -27.63M | -22.03M | -147.97M | -11.30M | 6.04M | -34.06M | -30.31M | -3.78M | -5.58M | 0.00 | -3.85M | -3.27M | -1.41M | -2.51M | -851.42K | -838.07K | -2.65M | -5.74M | -2.24M | -379.86K | -457.20K | -1.05M |
| EBITDA Ratio | -356.14% | -291.69% | -2,924.62% | -5,964.44% | -10,441.30% | -71,910.65% | -6,543.02% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,476.07% | -815.17% |
| Operating Income | -14.58M | -29.95M | -39.48M | -28.89M | -22.53M | -148.17M | -11.66M | -8.49M | -6.16M | -3.37M | -3.31M | -6.22M | -2.64M | -3.94M | -5.38M | -2.28M | -2.51M | -888.25K | -989.56K | -2.68M | -5.78M | -2.28M | -379.86K | -1.47M | -1.06M |
| Operating Income Ratio | -440.37% | -332.56% | -3,179.32% | -6,188.25% | -10,567.28% | -71,930.07% | -6,371.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,857.63% | -881.85% |
| Total Other Income/Expenses | 539.16K | 15.09K | -2.40M | 179.74K | 1.10M | 213.72K | 497.87K | 6.04M | -27.91M | -27.51M | -2.87M | -373.57K | 607.92K | -1.15M | -268.53K | -695.52K | -1.38M | -416.14K | 29.69K | 0.00 | 0.00 | 0.00 | -4.68K | 460.51K | -62.80K |
| Income Before Tax | -14.04M | -29.93M | -41.88M | -28.71M | -21.43M | -147.96M | -10.98M | -2.46M | -34.07M | -30.88M | -5.53M | -5.86M | -2.03M | -5.09M | -4.46M | -2.20M | -3.89M | -1.30M | -989.56K | -2.68M | -5.78M | -2.28M | -384.54K | -1.29M | -1.13M |
| Income Before Tax Ratio | -424.09% | -332.40% | -3,372.68% | -6,149.74% | -10,050.92% | -71,826.32% | -5,999.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,156.80% | -933.87% |
| Income Tax Expense | 3.68K | -15.09K | -5.70K | -179.74K | -1.10M | -213.72K | -680.93K | -6.04M | 27.90M | 26.94M | 466.28K | -1.11M | -1.29M | -93.84K | 4.46M | 2.20M | 3.89M | 1.30M | 989.56K | 2.68M | 5.78M | 2.28M | 384.54K | 1.29M | 1.13M |
| Net Income | -14.05M | -29.92M | -41.87M | -28.53M | -20.33M | -147.96M | -10.98M | -2.46M | -34.07M | -30.88M | -5.53M | -5.86M | -2.03M | -5.09M | -4.46M | -2.20M | -3.89M | -1.30M | -989.56K | -2.68M | -5.78M | -2.28M | -384.54K | -1.29M | -1.13M |
| Net Income Ratio | -424.20% | -332.23% | -3,372.22% | -6,111.23% | -9,534.57% | -71,826.32% | -5,999.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,156.80% | -933.87% |
| EPS | -1.93 | -3.58 | -5.47 | -6.06 | -4.46 | -77.50 | -11.62 | -3.56 | -93.02 | -239.63 | -584.40 | -1.07K | -529.47 | -1.54K | -1.40K | -1.12K | -2.24K | -1.30M | -989.56K | -2.68M | -5.78M | -2.28M | -384.54K | -1.29M | -1.13M |
| EPS Diluted | -1.93 | -3.58 | -5.47 | -6.06 | -4.46 | -77.50 | -11.62 | -3.31 | -93.02 | -239.63 | -584.40 | -1.07K | -529.47 | -1.54K | -1.40K | -1.12K | -2.24K | -1.30M | -989.56K | -2.68M | -5.78M | -2.28M | -384.54K | -1.29M | -1.13M |
| Weighted Avg Shares Out | 8.81M | 8.35M | 7.65M | 4.70M | 4.56M | 1.91M | 945.35K | 688.99K | 366.23K | 128.88K | 9.47K | 5.46K | 3.83K | 3.32K | 3.20K | 1.95K | 1.73K | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Weighted Avg Shares Out (Dil) | 8.81M | 8.35M | 7.65M | 4.70M | 4.56M | 1.91M | 945.35K | 742.10K | 366.23K | 128.88K | 9.47K | 5.46K | 3.83K | 3.32K | 3.20K | 1.95K | 1.73K | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
7 Low Float Penny Stocks To Watch After SNTG Stock Explodes
More low float penny stocks to watch. The post 7 Low Float Penny Stocks To Watch After SNTG Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Tops Revenue Estimates
MARKER THERAPEUTICS, INC. (MRKR) delivered earnings and revenue surprises of 38.46% and 393.75%, respectively, for the quarter ended September 2022.
3 Hot Penny Stocks To Buy For Under $1 Right Now
If you're watching the action in the stock market today, you're seeing plenty of chop. The U.S. dollar's strength has pushed broader markets lower, but a mix of positive and negative economic against this week's PPI data and CPI data...
Marker Therapeutics to Present at Two Upcoming March Investor Conferences
HOUSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Anthony H. Kim,...
Why Are Marker Therapeutics Shares Trading Lower On Thursday?
Marker Therapeutics Inc (NASDAQ: MRKR) shares are trading lower after Roth Capital downgrades the company from Buy to Neutral and lowers the price target from $3 to $1. The company reported initial results from the Phase 2 trial for MT-401 as a...
3 Penny Stocks Under $1 For You List This Week
Penny stocks to watch today The post 3 Penny Stocks Under $1 For You List This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Marker Therapeutics Stock Gains On FDA Orphan Drug Tag For Second MultiTAA-Cell Therapy For Pancreatic Cancer
The FDA has granted Orphan Drug Designation to Marker Therapeutics Inc's (NASDAQ: MRKR) MT-601, a multi-tumor-associated antigen (MultiTAA)-specific T cell product for pancreatic cancer. Following MT-401 for post-transplant acute myeloid leukemia (AML), MT-601 is Marker's second novel MultiTAA-specific T cell product to receive orphan...
Marker Therapeutics Secures $13.1M Grant To Support MultiTAA Cell Therapy Trial
Marker Therapeutics Inc (NASDAQ: MRKR) received notice of a Product Development Research award of approximately $13.1 million from Texas's Cancer Prevention and Research Institute (CPRIT). The CPRIT award is intended to support the adjuvant arm Phase 2 trial of its MultiTAA-specific T cell...
Marker Therapeutics Shares Increase Over 15% Pre-Market: Why It Happened
The shares of Marker Therapeutics, Inc. (Nasdaq: MRKR) increased by over 15% pre-market. This is why it happened.
Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas
HOUSTON, Aug. 19, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Company received notice of a...
Source: https://incomestatements.info
Category: Stock Reports